U.S. Effort To Close Patent Loophole Seen Affecting Indian Generics
This article was originally published in PharmAsia News
Executive Summary
Indian generics makers are expected to be among the most-affected by a U.S. decision to plug loopholes that allow brand-generic patent deals. The deals often involve a brand-name drug maker and generics makers reaching agreements to settle patent disputes. Ranbaxy Laboratories and Dr. Reddy's Laboratories have been involved in several settlements with major pharmas, helping to spark the U.S. Federal Trade Commission concern about anti-competitive practices. The agency threatened action to prevent the primary effect of the deals, which the FTC says delays the availability of the cheaper generics on the U.S. market. The action could include legislation to amend current law that allows the deals. (Click here for more
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.